Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Breast Neoplasms
Interventions
DRUG

sunitinib

sunitinib (Sutent), 37.5 mg, daily dosing

Trial Locations (31)

27103

Pfizer Investigational Site, Winston-Salem

27284

Pfizer Investigational Site, Kernersville

27292

Pfizer Investigational Site, Lexington

27599

Pfizer Investigational Site, Chapel Hill

28659

Pfizer Investigational Site, North Wilkesboro

28806

Pfizer Investigational Site, Asheville

33435

Pfizer Investigational Site, Boynton Beach

37066

Pfizer Investigational Site, Gallatin

37067

Pfizer Investigational Site, Franklin

37076

Pfizer Investigational Site, Hermitage

37087

Pfizer Investigational Site, Lebanon

37130

Pfizer Investigational Site, Murfreesboro

37167

Pfizer Investigational Site, Smyrna

37203

Pfizer Investigational Site, Nashville

37205

Pfizer Investigational Site, Nashville

37207

Pfizer Investigational Site, Nashville

37211

Pfizer Investigational Site, Nashville

40207

Pfizer Investigational Site, Louisville

49007

Pfizer Investigational Site, Kalamazoo

55369

Pfizer Investigational Site, Maple Grove

55454

Pfizer Investigational Site, Minneapolis

55455

Pfizer Investigational Site, Minneapolis

58501

Pfizer Investigational Site, Bismarck

60099

Pfizer Investigational Site, Zion

65203

Pfizer Investigational Site, Columbia

90250

Pfizer Investigational Site, Hawthorne

90806

Pfizer Investigational Site, Long Beach

92708

Pfizer Investigational Site, Fountain Valley

93309

Pfizer Investigational Site, Bakersfield

98201

Pfizer Investigational Site, Everett

91505-4866

Pfizer Investigational Site, Burbank

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY